drugset
drugset / Trial / NCT02565810

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

NCT02565810 ↗

Phase 2 Completed 49 enrolled Samsung Bioepis Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis.

Timeline

Start
2015-09
Primary completion
2016-03
Completion
2016-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications

rheumatoid arthritis